Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To compare the clinical outcomes of Endoscopic Lung Volume Reduction (ELVR) using Pulmonx Zephyr Valves vs. Standard of Care (SoC) in the treatment of heterogeneous emphysema subjects in a controlled trial design setting.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Endoscopic Lung Volume Reduction | Experimental | Patients are implanted with Zephyr Valves |
|
| Standard of Care | No Intervention | Patients are given Standard Medical Care |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves | Device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Forced Expiratory Volume in 1-second (FEV1) - Responders | The percentage of trial participants in the EBV treatment arm meeting the minimally clinically important difference (MCID) of >12% improved forced expiratory volume in one second (FEV1), obtained immediately following bronchodilator therapy, as compared to the percentage in the control arm at 3 months post-procedure. | Between baseline and 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| St George's Respiratory Questionnaire (SGRQ) - Absolute change | Absolute change in the SGRQ in the EBV treatment arm at 3, 6, 12, 18 and 24 months relative to Baseline and the difference between the two arms at 3, 6 and 12 months. The St. George's Respiratory Questionnaire measures health status (quality of life) in patients with diseases of airways obstruction. The questionnaire comprises of two parts: Part I: Symptoms (frequency & severity) Part II: Activities that cause or are limited by breathlessness; Impacts (social functioning, psychological disturbances resulting from airways disease) A Total score is calculated which summarizes the impact of the disease on overall health status. Scores range from 0 to 100, with higher scores indicating more limitations. |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Events | Adverse events (condition/procedure related AE's, SAE's, ADE's and SADE's) occurring up to 24 months post EBV placement and up to 12 months post randomization (for any remaining subjects in the SoC group). | Between baseline and 24 months |
| PaO2 - Absolute change |
Inclusion Criteria:
Additional inclusion criterion French CIP*:
- If treated in France, Subject must be entitled to French social security
Exclusion Criteria:
Additional exclusion criteria in the French CIP*:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gunnar Hillerdal, MD, PhD | Uppsala University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universiteit Gent | Ghent | 9000 | Belgium | |||
| AZ Delta |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39515624 | Derived | Bakker JT, Hartman JE, Klooster K, Charbonnier JP, Tsiaousis M, Vliegenthart R, Slebos DJ. Endobronchial valve treatment improves chest-CT diaphragm configuration in COPD. Respir Med. 2024 Nov-Dec;234:107856. doi: 10.1016/j.rmed.2024.107856. Epub 2024 Nov 6. | |
| 28885054 | Derived | Kemp SV, Slebos DJ, Kirk A, Kornaszewska M, Carron K, Ek L, Broman G, Hillerdal G, Mal H, Pison C, Briault A, Downer N, Darwiche K, Rao J, Hubner RH, Ruwwe-Glosenkamp C, Trosini-Desert V, Eberhardt R, Herth FJ, Derom E, Malfait T, Shah PL, Garner JL, Ten Hacken NH, Fallouh H, Leroy S, Marquette CH; TRANSFORM Study Team *. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM). Am J Respir Crit Care Med. 2017 Dec 15;196(12):1535-1543. doi: 10.1164/rccm.201707-1327OC. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Between Baseline and 3, 6, 12, 18 and 24 months |
| St George's Respiratory Questionnaire (SGRQ) - Percent change | Percent change in the SGRQ in the EBV treatment arm at 3, 6, 12, 18 and 24 months relative to Baseline and the difference between the two arms at 3, 6 and 12 months. The St. George's Respiratory Questionnaire measures health status (quality of life) in patients with diseases of airways obstruction. The questionnaire comprises of two parts: Part I: Symptoms (frequency & severity) Part II: Activities that cause or are limited by breathlessness; Impacts (social functioning, psychological disturbances resulting from airways disease) A Total score is calculated which summarizes the impact of the disease on overall health status. Scores range from 0 to 100, with higher scores indicating more limitations. | Between Baseline and 3, 6, 12, 18 and 24 months |
| St George's Respiratory Questionnaire (SGRQ) - Responders | Percentage of subject achieving the MCID for SGRQ in the EBV treatment arm at 3, 6, 12, 18 and 24 months, compared to SoC at 3, 6 and 12 months. The St. George's Respiratory Questionnaire measures health status (quality of life) in patients with diseases of airways obstruction. The questionnaire comprises of two parts: Part I: Symptoms (frequency & severity) Part II: Activities that cause or are limited by breathlessness; Impacts (social functioning, psychological disturbances resulting from airways disease) A Total score is calculated which summarizes the impact of the disease on overall health status. Scores range from 0 to 100, with higher scores indicating more limitations. | Between Baseline and 3, 6, 12, 18 and 24 months |
| 6-minute walk distance (6MWT) - Absolute change | Absolute change in 6MWD in the EBV treatment arm at 3, 6, 12, 18, 24 months relative to Baseline and the difference between the two arms at 3, 6 and 12 months. | Between Baseline and 3, 6, 12, 18, 24 months |
| 6-minute walk distance (6MWT) - Percent change | Percent change in 6MWD in the EBV treatment arm at 3, 6, 12, 18, 24 months relative to Baseline and the difference between the two arms at 3, 6 and 12 months. | Between Baseline and 3, 6, 12, 18, 24 months |
| 6-minute walk distance (6MWT) - Responders | Percentage of subject achieving the MCID for 6MWD in the EBV treatment arm at 3, 6, 12, 18 and 24 months, compared to SoC at 3, 6 and 12 months. | Between Baseline and 3, 6, 12, 18, 24 months |
| Forced Expiratory Volume in 1-second (FEV1) - Absolute change | Absolute change in FEV1 in the EBV treatment arm at 3, 6, 12, 18, 24 months relative to Baseline and the difference between the two arms at 3, 6 and 12 months. | Between Baseline and 3, 6, 12, 18, 24 months |
| Forced Expiratory Volume in 1-second (FEV1) - Percent change | Percentage of subject achieving the MCID for FEV1 in the EBV treatment arm at 6, 12, 18 and 24 months, compared to SoC at 6 and 12 months. | Between Baseline and 6, 12, 18 and 24 months |
| Forced Expiratory Volume in 1-second (FEV1) - Responders | Absolute change in FEV1 in the EBV treatment arm at 3, 6, 12, 18, 24 months relative to Baseline and the difference between the two arms at 3, 6 and 12 months. | Between Baseline and 3, 6, 12, 18, 24 months |
| mMRC (Modified Medical Research Council) score - Responders | Percentage of subject in the EBV treatment arm achieving the MCID for the Modified Scale Research Council Dyspnea Score (mMRC) at 3, 6, 12, 18 and 24 months and the difference between the two arms at 3, 6 and 12 months. The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations. | Between Baseline and 3, 6, 12, 18 and 24 months |
| Target Lobar Volume Reduction (TLVR) - Absolute change | Absolute change in target lobe volume at 45 days in the EBV treatment arm relative to Baseline as assessed by quantitative HRCT analysis (TLVR: Target Lobar Volume Reduction). | Between baseline and 45 days |
| Target Lobar Volume Reduction (TLVR) - Percent change | Percent change in target lobe volume at 45 days in the EBV treatment arm relative to Baseline as assessed by quantitative HRCT analysis (TLVR: Target Lobar Volume Reduction). | Between baseline and 45 days |
| Target Lobar Volume Reduction (TLVR) - Responders | Percentage of subjects in EBV arm with a TLVR > 350ml at 45 days relative to baseline. | Between baseline and 45 days |
Absolute change in PaO2 in the EBV treatment arm at 3 months relative to Baseline. |
| Between baseline and 3 months |
| PaO2 - Percent change | Percent change in PaO2 in the EBV treatment arm at 3 months relative to Baseline. | Between baseline and 3 months |
| Residual Volume (RV) - Absolute change | Absolute change in residual volume (RV) in the EBV treatment arm at 3, 6 and 12, 18 and 24 months relative to Baseline and the difference between the two arms at 3, 6 and 12 months. | Between Baseline and 3, 6 and 12, 18 and 24 months |
| Residual Volume (RV) - Percent change | Percent change in residual volume (RV) in the EBV treatment arm at 3, 6 and 12, 18 and 24 months relative to Baseline and the difference between the two arms at 3, 6 and 12 months. | Between Baseline and 3, 6 and 12, 18 and 24 months |
| EQ-5D Summary Index - Absolute change | Absolute change relative to Baseline in the EBV treatment arm at 3, 6, 12, 18 and 24 months of the EQ-5D Summary Index and the difference between the two arms at, 3, 6 and 12 months. EQ-5D is a standardized instrument used to measure health-related quality of life for a wide range of health conditions and treatments. The EQ-5D consists of a descriptive system and the EQ VAS. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale. This can be used as a quantitative measure of health outcome that reflects the patient's own judgement. The scores on these five dimensions can be presented as a health profile or can be converted to a single summary index number (utility) reflecting preferability compared to other health profiles. | Between Baseline and 3, 6, 12, 18 and 24 months |
| EQ-5D Summary Index Percent change | Percent change relative to Baseline in the EBV treatment arm at 3, 6, 12, 18 and 24 months of the EQ-5D Summary Index and the difference between the two arms at, 3, 6 and 12 months. EQ-5D is a standardized instrument used to measure health-related quality of life for a wide range of health conditions and treatments. The EQ-5D consists of a descriptive system and the EQ VAS. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale. This can be used as a quantitative measure of health outcome that reflects the patient's own judgement. The scores on these five dimensions can be presented as a health profile or can be converted to a single summary index number (utility) reflecting preferability compared to other health profiles. | Between Baseline and 3, 6, 12, 18 and 24 months |
| Mean number of additional hospitalizations and/or visits caused by respiratory conditions | The mean number of visits (Number of participants reporting visits/total number of visits) caused by respiratory conditions during the study period will be recorded for health economical purposes in both treatment and control subjects. | Between baseline and 24 months |
| Menen |
| 8930 |
| Belgium |
| CHU | Grenoble | 38043 | France |
| CHU Hôpital Pasteur | Nice | 06002 | France |
| Groupe Hospitalier Pitié Salpétrière | Paris | 75013 | France |
| Hôpital Bichat Claude Bernard | Paris | 75877 | France |
| Charité Campus Virchow-Klinikum | Berlin | 13353 | Germany |
| Ruhrlandklinik Westdeutsches Lungenzentrum | Essen | 45239 | Germany |
| Thoraxklinik am Universitäts Klinikum Heidelberg | Heidelberg | 69126 | Germany |
| University Medical Center Groningen | Groningen | 9700 | Netherlands |
| Skane University Hospital | Lund | 221 85 | Sweden |
| Uppsala University Hospital | Uppsala | 751 85 | Sweden |
| Sherwood Forest Hospitals NHS | Sutton in Ashfield | Nottinghamshire | NG17 4JL | United Kingdom |
| West of Scotland Regional Heart & Lung Centre - Golden Jubilee National Hospital | Clydebank | West Dunbartonshire Scotland | G81 4DY | United Kingdom |
| University Hospital of Wales | Cardiff | CF144XW | United Kingdom |
| The Royal Brompton Hospital & Harefield NHS Foundation Trust | London | SW3 6NP | United Kingdom |
| Sheffield Teaching Hospitals NHS Foundation Trust | Sheffield | S5 7AU | United Kingdom |
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D011013 | Pneumonectomy |
| ID | Term |
|---|---|
| D013514 | Surgical Procedures, Operative |
| D013510 | Pulmonary Surgical Procedures |
| D019616 | Thoracic Surgical Procedures |
Not provided
Not provided